Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36

Benzinga Newsdesk www.benzinga.com Positive 79.6%

Neg 0% Neu 0% Pos 79.6%

Leerink Partners initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $36.